10 years in development kind of disqualifies Cryoport from entitlement to the nomenclature of "start-up", and I would consider submerging stock, as a much more appropriate description of CYRX than emerging.
Unfortunately, your betting on Cryoport being the next home run, isn't going to make much of a difference. Without institutional participation, CYRX stands about as much of a chance of trading higher, as the CUBS probability of winning the World Series in 2011.
And unfortunately once again, we all know that institutional fund managers look at certain performance metrics of a company, before they purchase a prospective company's stock for their fund, i.e., revenue, EBITDA, etc. How else can they come up with a valuation for the company , and determine if the SP is overvalued or undervalued?
A good story from the mouth of the CEO or the IR/PR person, might be good enough for you, but it ain't gonna cut it for a professional fund manager.
CYRX will be trading between $0.40 and $0.50 by the end of the year.
News 
Market Data 
Discover 
